Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-08-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2022 年半年度报告全文" which translates to "2022 Semi-Annual Report Full Text". It contains detailed financial data, management discussion and analysis, company overview, business segments, financial indicators, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2022 to June 30, 2022, which is a half-year period, consistent with an interim report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. There is no indication that this is an annual report (10-K) or a full year report, nor is it a regulatory filing or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Governance Information Classification · 95% confidence The document is an independent directors' special statement and opinion regarding the company's external guarantees and fund occupation for the half-year period ending June 30, 2022. It references compliance with regulatory notices from the China Securities Regulatory Commission and discusses internal governance and financial oversight matters. The document is a formal opinion by independent directors on specific governance and financial issues, not a full financial report or audit report. It is not an announcement of voting results, management changes, or a call transcript. The content aligns with a governance-related report focusing on compliance and oversight rather than a full audit or annual report. Therefore, the best fitting category is 'Governance Information (CGR)'. The document length (996 characters) and content support this classification with high confidence.
2022-08-24 Chinese
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2022 年半年度财务报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2022 Semi-Annual Financial Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and equity changes for the half-year period ending June 30, 2022. The document explicitly states it is a semi-annual report and includes comprehensive financial data and analysis for the period. It is not an announcement or a brief summary but a full financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
半年报董事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a formal announcement of the board of directors' meeting resolution approving the 2022 semi-annual report and its summary. It references the actual semi-annual report being published elsewhere (on the official information disclosure platform and newspapers) but does not contain the report itself or detailed financial data. The document length is short (578 characters), and it serves as a notice of the board's approval and the publication of the interim report, not the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2022-08-24 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary' for Shenzhen Haier Bioengineering Co., Ltd. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses shareholder information, changes in controlling shareholders, and important company events during the reporting period. The document is about 3,832 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-24 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2022. It includes specific financial figures such as balances, cumulative amounts, interest, and repayments related to various related parties and subsidiaries. The presence of detailed financial data for a half-year period indicates this is a substantive financial report rather than a brief announcement or certification. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains actual financial data and analysis related to the company's financial dealings during that period. H1 2022
2022-08-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.